Pharmaceutical company Nectar Lifesciences (NSE:NECLIFE, BOM:532649) has agreed to sell its core business division--comprising the manufacture, distribution, and marketing of active pharmaceutical ingredients (APIs) and formulations--to Ceph Lifesciences for 12.70 billion Indian rupees, according to a Tuesday filing to the Indian bourses.
The company has also agreed to sell its menthol business assets to Ceph Lifesciences for 200 million rupees.
The transactions are expected to be completed by Sept. 25.
The move is part of the company's long-term strategy to streamline its operations and strengthen its financial position.
The company plans to use the proceeds from the sale to repay existing debt, invest in new and emerging business, reward shareholders, and to fund future corporate and growth initiatives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.